121 related articles for article (PubMed ID: 1421033)
21. Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer.
Cooper EH; Whelan P; Purves D
Prostate; 1994 Nov; 25(5):236-42. PubMed ID: 7526352
[TBL] [Abstract][Full Text] [Related]
22. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases.
Berruti A; Dogliotti L; Gorzegno G; Torta M; Tampellini M; Tucci M; Cerutti S; Frezet MM; Stivanello M; Sacchetto G; Angeli A
Clin Chem; 1999 Aug; 45(8 Pt 1):1240-7. PubMed ID: 10430790
[TBL] [Abstract][Full Text] [Related]
23. Identification of bone and liver metastases from breast cancer by measurement of plasma alkaline phosphatase isoenzyme activity.
Mayne PD; Thakrar S; Rosalki SB; Foo AY; Parbhoo S
J Clin Pathol; 1987 Apr; 40(4):398-403. PubMed ID: 3584482
[TBL] [Abstract][Full Text] [Related]
24. Expressiveness of Bone Markers in Breast Cancer with Bone Metastases.
Zulauf N; Brüggmann D; Groneberg D; Oremek GM
Oncology; 2019; 97(4):236-244. PubMed ID: 31412345
[TBL] [Abstract][Full Text] [Related]
25. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
[TBL] [Abstract][Full Text] [Related]
26. Comparison of bone and total alkaline phosphatase activity on bone turnover during menopause and in patients with established osteoporosis.
Takahashi M; Kushida K; Hoshino H; Miura M; Ohishi T; Inoue T
Clin Endocrinol (Oxf); 1997 Aug; 47(2):177-83. PubMed ID: 9302392
[TBL] [Abstract][Full Text] [Related]
27. Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer?
Bombardieri E; Martinetti A; Miceli R; Mariani L; Castellani MR; Seregni E
Eur J Nucl Med; 1997 Nov; 24(11):1349-55. PubMed ID: 9371866
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of simultaneous determination of bone alkaline phosphatase mass concentration in serum and urinary excretion of pyridinium cross-links for detection of bone metastases.
Withold W; Georgescu G; Khakzad H; Vosberg H; Mueller-Gaertner HW; Reinauer H
Clin Biochem; 1995 Oct; 28(5):511-9. PubMed ID: 8582050
[TBL] [Abstract][Full Text] [Related]
29. Biochemical markers and skeletal metastases.
Demers LM; Costa L; Lipton A
Cancer; 2000 Jun; 88(12 Suppl):2919-26. PubMed ID: 10898335
[TBL] [Abstract][Full Text] [Related]
30. Plasma acid and alkaline phosphatase in patients with breast cancer.
Nguyen M; Bonneterre J; Hecquet B; Desoize B; Demaille A
Anticancer Res; 1991; 11(2):831-3. PubMed ID: 2064338
[TBL] [Abstract][Full Text] [Related]
31. Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results.
Lumachi F; Marino F; Fanti G; Chiara GB; Basso SM
Anticancer Res; 2011 Nov; 31(11):3879-81. PubMed ID: 22110213
[TBL] [Abstract][Full Text] [Related]
32. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
Morote J; Lorente JA; Encabo G
Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
[TBL] [Abstract][Full Text] [Related]
33. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients.
Lorente JA; Valenzuela H; Morote J; Gelabert A
Eur J Nucl Med; 1999 Jun; 26(6):625-32. PubMed ID: 10369948
[TBL] [Abstract][Full Text] [Related]
34. Bone alkaline phosphatase in Paget's disease.
Deftos LJ; Wolfert RL; Hill CS
Horm Metab Res; 1991 Nov; 23(11):559-61. PubMed ID: 1816067
[TBL] [Abstract][Full Text] [Related]
35. Sequential estimation of alkaline phosphatase isoenzymes (API) in breast cancer patients.
Horner GU; Caffier HO
Cancer Detect Prev; 1981; 4(1-4):205-9. PubMed ID: 7349778
[TBL] [Abstract][Full Text] [Related]
36. Alkaline phosphatase isoenzymes in detection and follow up of breast cancer metastases.
Ritzke C; Stieber P; Untch M; Nagel D; Eiermann W; Fateh-Moghadam A
Anticancer Res; 1998; 18(2B):1243-9. PubMed ID: 9615795
[TBL] [Abstract][Full Text] [Related]
37. Bone alkaline phosphatase in rheumatic diseases.
Beyeler C; Banks RE; Thompson D; Forbes MA; Cooper EH; Bird H
Ann Clin Biochem; 1995 Jul; 32 ( Pt 4)():379-84. PubMed ID: 7486797
[TBL] [Abstract][Full Text] [Related]
38. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.
Korpela J; Tiitinen SL; Hiekkanen H; Halleen JM; Selander KS; Väänänen HK; Suominen P; Helenius H; Salminen E
Anticancer Res; 2006; 26(4B):3127-32. PubMed ID: 16886645
[TBL] [Abstract][Full Text] [Related]
39. [Measurement of skeletal alkaline phosphatase in prostatic carcinoma. Preliminary report].
Casetta G; Gamba P; Piana P; Pecchio F; Tizzani A
Minerva Urol Nefrol; 1995 Mar; 47(1):9-12. PubMed ID: 7570264
[TBL] [Abstract][Full Text] [Related]
40. Comparison of total and bone-specific alkaline phosphatase in patients with nonskeletal disorder or metabolic bone diseases.
Woitge HW; Seibel MJ; Ziegler R
Clin Chem; 1996 Nov; 42(11):1796-804. PubMed ID: 8906079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
